GL1X · GenesisL1 explorer

Research workbench

EGFR (L858R, T790M, V948R) in complex with N-[3-({2-[(1-methyl-1H- pyrazol-4-YL)AMINO]-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- 2-enamide

Analyse EGFR (L858R, T790M, V948R) in complex with N-[3-({2-[(1-methyl-1H… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
5HG8
Type
protein
Length
300 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Epidermal growth factor receptor
EC
2.7.10.1
UniProt
P00533
Ligands
634, SO4
Pockets
2 · best druggability 0.70

Structure

x-ray diffraction · 1 distinct chain · 38% helix, 20% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AEpidermal growth factor receptor (EC 2.7.10.1)protein30038% helix, 20% strandP00533

Ligands and binding sites

  • 634 · N-[3-({2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)phenyl]propanamide · ligand · chains A
  • SO4 · Sulfate ion · ion · 2 copies · chains A
  • GOL · Glycerol · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
14250.700.8143empty
21380.500.7923634

Modifications

Observed in the structure: 1 covalent (covalent ligand).

Compared structures

  • 5HG8 · EGFR (L858R, T790M, V948R) in complex with N-[3-({2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-p… · the same entry in another collection · chain A against A, TM-score 1.00
  • P00533 · AlphaFold monomer V2.0 prediction for epidermal growth factor receptor (P00533) · a predicted model of the same protein · chain A against A, TM-score 0.93

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.